The KCTD2 Knockout HeLa Polyclonal Cells are a polyclonal knockout cell product generated via CRISPR/Cas9-mediated gene disruption of the endogenous KCTD2 locus in HeLa cells. As a polyclonal pool, this population comprises a mixture of edited cells, each potentially harboring distinct mutations, which collectively ensures loss-of-function while preserving the biological variability that can enhance experimental robustness. This model enables researchers to systematically interrogate the contributions of KCTD2 to ubiquitin-proteasome pathway dynamics and cancer cell biology.
Derived from a cervical adenocarcinoma, HeLa is an immortalized epithelial cell line widely used as a cancer model. It harbors integrated HPV18 DNA, expressing the viral oncogenes E6 and E7, which target and inactivate the tumor suppressors p53 and retinoblastoma protein (RB), respectively. This oncogenic landscape deregulates cell cycle control and apoptosis, providing a permissive background for probing additional genetic perturbations such as KCTD2 knockout. Thus, this cell model is exceptionally suited for studying ubiquitin signaling in the context of HPV-driven carcinogenesis.
KCTD2 functions as a substrate recognition adaptor for the CUL3-RBX1 E3 ubiquitin ligase complex, mediating ubiquitination and subsequent proteasomal degradation of target proteins. It directly interacts with CUL3 and RBX1, recruiting specific substrates such as histone deacetylase 1 (HDAC1) for ubiquitin tagging. Transcription of KCTD2 may be regulated by the proto-oncogene MYC, thus integrating proliferative cues with protein turnover. In the absence of KCTD2, substrates like HDAC1 are stabilized, potentially altering chromatin remodeling and gene expression networks. This disruption can affect cell cycle progression, protein quality control, and oncogenic signaling, underscoring the adaptor??s pivotal role in maintaining proteostasis within the CUL3-RBX1-KCTD2-ubiquitin-proteasome axis.
In the HeLa context, KCTD2 knockout allows dissection of ubiquitin-dependent degradation pathways that intersect with HPV oncoprotein activities. Given that KCTD2 is associated with glioma and cervical cancer, this polyclonal model facilitates investigation of its role across tumor types. The combination of HPV-mediated tumor suppressor inactivation and KCTD2 deficiency permits functional dissection of substrate turnover, evaluation of synthetic lethal interactions, and exploration of vulnerabilities specific to cancer cells with compromised ubiquitin-proteasome system regulation.
Typical research applications involve the use of these cells in ubiquitination assays to monitor substrate degradation, co-immunoprecipitation to assess CUL3 complex formation, and western blotting to verify endogenous KCTD2 knockout and target protein stabilization. Additionally, cell viability and proliferation assays can evaluate the impact of KCTD2 loss on cancer cell fitness, while RT-qPCR enables quantification of downstream transcriptional changes. These polyclonal KCTD2 knockout cells are also suitable for proteasome activity assays and functional genomics screens aimed at identifying drug targets within the ubiquitin-proteasome system. For further product details or technical support, please contact Ascent Research.
